ReviewAmerican journal of clinical dermatology2022
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.
Review in American journal of clinical dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
- JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases.Frontiers in immunology · 2026Review
- Understanding Atopic Dermatitis: Pathophysiology and Management Strategies.Biomolecules · 2025Review
- Biologics and Small-Molecule Therapies in Netherton Syndrome: A Comprehensive Review.The Journal of dermatology · 2025Review
- Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.Current issues in molecular biology · 2025Review
- Engineered Tissue Models to Decode Host-Microbiota Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Article
- Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies.Frontiers in immunology · 2025Review
- Baricitinib in the treatment of atopic dermatitis: a systematic review of randomized controlled trials.Postepy dermatologii i alergologii · 2025Review
- Neutrophils in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2024Review
- Systems Biology Methods via Genome-Wide RNA Sequences to Investigate Pathogenic Mechanisms for Identifying Biomarkers and Constructing a DNN-Based Drug-Target Interaction Model to Predict Potential Molecular Drugs for Treating Atopic Dermatitis.International journal of molecular sciences · 2024Article
- Fungal Head and Neck Dermatitis: Current Understanding and Management.Clinical reviews in allergy & immunology · 2024Review
- The Future of Atopic Dermatitis Treatment.Advances in experimental medicine and biology · 2024Review
- Real-World Effectiveness and Safety of Baricitinib in Patients with Atopic Dermatitis.Clinical drug investigation · 2024Article
- Biologics and oral small-molecule inhibitors for treatment of pediatric atopic dermatitis: Opportunities and challenges.Pediatric investigation · 2023Review
- Baricitinib: A Review in Severe Alopecia Areata.American journal of clinical dermatology · 2023Review
- Article
- Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents.Frontiers in medicine · 2023Review
- Consensus on the therapeutic management of atopic dermatitis ‒ Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique.Anais brasileiros de dermatologiaArticle
- Emerging Role of Baricitinib in Dermatology Practice: All We Need to Know!Indian dermatology online journalReview
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baricitinib (Olumiant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.